PMID- 37947195
OWN - NLM
STAT- MEDLINE
DCOM- 20240108
LR  - 20240108
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 24
IP  - 18
DP  - 2023 Sep-Dec
TI  - Psychedelics for treatment resistant depression: are they game changers?
PG  - 2117-2132
LID - 10.1080/14656566.2023.2281582 [doi]
AB  - INTRODUCTION: A new era of treatment for adults with treatment-resistant 
      depression (TRD), which involves psychedelic substances, is dawning. Emerging 
      evidence indicates that psychedelics can exert antidepressant effects through 
      multiple neurobiological and psychological mechanisms. However, it remains to be 
      seen if these new treatments will revolutionize the treatment of TRD. AREAS 
      COVERED: The present review focuses on the efficacy of serotoninergic 
      psychedelics psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine 
      (DMT), ayahuasca, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and mescaline 
      (3,4,5-trimethoxyphenethylamine), as well as 3,4-methylenedioxymethamphetamine 
      (MDMA), for TRD. A systematic search was conducted for psilocybin in TRD as 
      emerging trials had not yet been subject to review. A narrative review summarized 
      findings on other psychedelics. EXPERT OPINION: Psychedelic therapy has created a 
      paradigm shift in the treatment of TRD, as it can maximize therapeutic benefits 
      and minimize potential risks. Psilocybin holds promise as a potential 
      game-changer in the treatment of TRD, with initial evidence suggesting a rapid 
      antidepressant effect sustained for some responders for at least 3 months. 
      Nevertheless, further adequately powered, double-blind, comparator-controlled 
      trials are required to explore and clarify the mechanisms of action and long-term 
      effects of psychedelics in TRD. Psychedelics also hold promise for other 
      psychiatric conditions, such as bipolar depression and post-traumatic stress 
      disorder.
FAU - Kalfas, Michail
AU  - Kalfas M
AUID- ORCID: 0000-0003-3029-9149
AD  - Department of Psychological Medicine, King's College London, London, UK.
FAU - Taylor, Rosie H
AU  - Taylor RH
AUID- ORCID: 0000-0001-6742-4842
AD  - Department of Psychological Medicine, King's College London, London, UK.
FAU - Tsapekos, Dimosthenis
AU  - Tsapekos D
AUID- ORCID: 0000-0002-1972-4813
AD  - Department of Psychological Medicine, King's College London, London, UK.
FAU - Young, Allan H
AU  - Young AH
AUID- ORCID: 0000-0003-2291-6952
AD  - Department of Psychological Medicine, King's College London, London, UK.
AD  - South London and Maudsley NHS Foundation Trust, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240105
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Hallucinogens)
RN  - 2RV7212BP0 (Psilocybin)
RN  - 8NA5SWF92O (Lysergic Acid Diethylamide)
RN  - RHO99102VC (Mescaline)
RN  - WUB601BHAA (N,N-Dimethyltryptamine)
RN  - 0 (Antidepressive Agents)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Hallucinogens/pharmacology/therapeutic use
MH  - Psilocybin/pharmacology/therapeutic use
MH  - *Depressive Disorder, Treatment-Resistant/drug therapy
MH  - Lysergic Acid Diethylamide/pharmacology/therapeutic use
MH  - Mescaline
MH  - N,N-Dimethyltryptamine
MH  - Antidepressive Agents/pharmacology/therapeutic use
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Psychedelics
OT  - major depressive disorder
OT  - psilocybin
OT  - systematic review
OT  - treatment resistant depression
EDAT- 2023/11/10 12:47
MHDA- 2024/01/08 06:42
CRDT- 2023/11/10 06:48
PHST- 2024/01/08 06:42 [medline]
PHST- 2023/11/10 12:47 [pubmed]
PHST- 2023/11/10 06:48 [entrez]
AID - 10.1080/14656566.2023.2281582 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2023 Sep-Dec;24(18):2117-2132. doi: 
      10.1080/14656566.2023.2281582. Epub 2024 Jan 5.